$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000145368721000069 Filed on May 13, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$11.05M	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.200M	$4.100M
YoY Change	26.83%	-9.09%
% of Gross Profit
Research & Development	$13.00M	$14.72M
YoY Change	-11.68%	100.24%
% of Gross Profit
Depreciation & Amortization	$100.0K	$200.0K
YoY Change	-50.0%	10.5%
% of Gross Profit
Operating Expenses	$18.21M	$18.82M
YoY Change	-3.26%	58.62%
Operating Profit	-$7.158M	-$18.82M
YoY Change	-61.97%	58.76%
Interest Expense	$711.0K	$273.0K
YoY Change	160.44%	-31.06%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.000K
YoY Change	-100.0%	-98.55%
Pretax Income	-$24.60M	-$19.62M
YoY Change	25.38%	62.55%
Income Tax
% Of Pretax Income
Net Earnings	-$24.60M	-$19.62M
YoY Change	25.37%	62.5%
Net Earnings / Revenue	-222.6%
Basic Earnings Per Share	-$0.22
Diluted Earnings Per Share	-$0.22	-$207.1K
COMMON SHARES
Basic Shares Outstanding	110.7M shares	86.42M shares
Diluted Shares Outstanding	110.7M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$147.8M	$72.60M
YoY Change	103.6%	50.0%
Cash & Equivalents	$125.4M	$72.61M
Short-Term Investments	$22.41M
Other Short-Term Assets	$7.000M	$1.900M
YoY Change	268.42%	2400.0%
Inventory
Prepaid Expenses
Receivables	$8.342M	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$163.1M	$74.44M
YoY Change	119.14%	25.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.301M	$1.134M
YoY Change	14.73%	-36.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.600M	$1.400M
YoY Change	14.29%
Total Long-Term Assets	$13.62M	$14.36M
YoY Change	-5.15%	386.12%
TOTAL ASSETS
Total Short-Term Assets	$163.1M	$74.44M
Total Long-Term Assets	$13.62M	$14.36M
Total Assets	$176.7M	$88.80M
YoY Change	99.04%	42.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$594.0K	$1.330M
YoY Change	-55.34%	91.92%
Accrued Expenses	$6.847M	$8.775M
YoY Change	-21.97%	3.24%
Deferred Revenue	$75.76M	$1.674M
YoY Change	4425.93%	74.56%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$500.0K	$16.90M
YoY Change	-97.04%	-21.4%
Total Short-Term Liabilities	$84.61M	$30.07M
YoY Change	181.35%	-9.0%
LONG-TERM LIABILITIES
Long-Term Debt	$24.60M	$0.00
YoY Change
Other Long-Term Liabilities	$87.20M	$67.50M
YoY Change	29.19%	8326.97%
Total Long-Term Liabilities	$111.8M	$67.50M
YoY Change	65.63%	8326.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$84.61M	$30.07M
Total Long-Term Liabilities	$111.8M	$67.50M
Total Liabilities	$196.3M	$97.56M
YoY Change	101.22%	104.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$429.2M	-$355.4M
YoY Change	20.77%	5.84%
Common Stock	$11.00K	$9.000K
YoY Change	22.22%	80.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$19.57M	-$8.763M
YoY Change
Total Liabilities & Shareholders Equity	$176.7M	$88.80M
YoY Change	99.04%	42.12%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$24.60M	-$19.62M
YoY Change	25.37%	62.5%
Depreciation, Depletion And Amortization	$100.0K	$200.0K
YoY Change	-50.0%	10.5%
Cash From Operating Activities	-$12.13M	-$11.70M
YoY Change	3.72%	-42.2%
INVESTING ACTIVITIES
Capital Expenditures	$25.00K	$135.0K
YoY Change	-81.48%
Acquisitions
YoY Change
Other Investing Activities	-$22.42M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$22.45M	-$135.0K
YoY Change	16525.93%	-99.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$20.99M	$1.141M
YoY Change	1739.7%	-96.31%
Debt Paid & Issued, Net	$0.00	$2.100M
YoY Change	-100.0%
Cash From Financing Activities	$21.31M	-$5.370M
YoY Change	-496.78%	-117.26%
NET CHANGE
Cash From Operating Activities	-$12.13M	-$11.70M
Cash From Investing Activities	-$22.45M	-$135.0K
Cash From Financing Activities	$21.31M	-$5.370M
Net Change In Cash	-$13.28M	-$17.29M
YoY Change	-23.19%	230.54%
FREE CASH FLOW
Cash From Operating Activities	-$12.13M	-$11.70M
Capital Expenditures	$25.00K	$135.0K
Free Cash Flow	-$12.16M	-$11.83M
YoY Change	2.75%	-41.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-37798
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Selecta Biosciences, Inc
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1622110
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	65 Grove Street,
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown,
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
CY2021Q1	dei	City Area Code CityAreaCode	617
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	923-1400
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	SELB
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	113193597	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125407000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138685000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	22405000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8342000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7224000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6971000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5434000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	163125000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	151343000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1301000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1395000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10676000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10948000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2021Q1	us-gaap	Other Assets OtherAssets	265000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	370000	USD
CY2021Q1	us-gaap	Assets Assets	176746000	USD
CY2020Q4	us-gaap	Assets Assets	165435000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	594000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	443000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6847000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8146000	USD
CY2021Q1	us-gaap	Loans Payable Current LoansPayableCurrent	460000	USD
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	942000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	908000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	75764000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	72050000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	84607000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	81547000	USD
CY2021Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	24551000	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	24793000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9403000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9647000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32301000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	38746000	USD
CY2021Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	45455000	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	28708000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	196317000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	183441000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112977004	shares
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	2300000	USD
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112977004	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108071249	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	108071249	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	414214000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	391175000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-429226000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-404629000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4570000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4563000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-19571000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-18006000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	176746000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165435000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11050000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13004000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14724000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5204000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4098000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	18208000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	18822000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7158000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18822000	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	12000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	240000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	82000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	711000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	273000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16747000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	846000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19620000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24604000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19680000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	110742150	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94723513	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-18006000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	72000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20943000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1780000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-19571000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	8397000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	114000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1141000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-147000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1409000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19620000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-8763000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-24597000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19620000	USD
CY2021Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	207000	USD
CY2020Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	231000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-14000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	272000	USD
CY2020Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	366000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1780000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1409000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	387000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	123000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16747000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	846000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1118000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5000000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1512000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	61000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	151000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	836000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2728000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1736000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-829000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12133000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11698000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	22420000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	135000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22445000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-135000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2100000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20991000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1141000	USD
CY2021Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4381000	USD
CY2021Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2020Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-147000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	244000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	72000	USD
CY2020Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	196850	shares
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	114000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21307000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5370000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-7000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-84000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13278000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17287000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140064000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91551000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126786000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74264000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	494000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	232000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2021Q1	selb	Equity Offering Costs In Accrued Liabilities EquityOfferingCostsInAccruedLiabilities	48000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	400000	USD
CY2020Q1	selb	Equity Offering Costs In Accrued Liabilities EquityOfferingCostsInAccruedLiabilities	42000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2021Q1	selb	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	149200000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1400000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-429200000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22406000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22405000	USD
CY2021Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24597000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19620000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	110742150	shares
CY2020Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.54
CY2020Q3	selb	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P10Y
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94723513	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23109723	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31000369	shares
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0	USD
CY2021Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125407000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72606000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	279000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1379000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126786000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74264000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5681000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5650000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4380000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4255000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1301000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1395000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2021Q1	selb	Accrued Interest Current AccruedInterestCurrent	170000	USD
CY2020Q4	selb	Accrued Interest Current AccruedInterestCurrent	170000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1840000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3049000	USD
CY2021Q1	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1350000	USD
CY2020Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1350000	USD
CY2021Q1	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	471000	USD
CY2020Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	534000	USD
CY2021Q1	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2010000	USD
CY2020Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2029000	USD
CY2021Q1	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	802000	USD
CY2020Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	798000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	204000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	216000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6847000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8146000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10676000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10948000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	942000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	908000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9403000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9647000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10345000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10555000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	444000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	472000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	288000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	199000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	735000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	673000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1368000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1866000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1922000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1980000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2039000	USD
CY2021Q1	selb	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4945000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14120000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3775000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10345000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	444000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	487000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	108100000	USD
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12378016000	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.60
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112977004	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112977004	shares
CY2021Q1	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1	vote
CY2021Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	30928290	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25157139	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1780000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1409000	USD
CY2021Q1	selb	Share Based Goods And Non Employee Services Transaction Compensation Not Yet Recognized Stock Options ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions	0	USD
CY2021Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	100000	USD
CY2020Q4	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	110796000	USD
CY2021Q1	selb	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	0	USD
CY2021Q1	selb	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	2730000	USD
CY2021Q1	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	108066000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	110796000	USD
CY2021Q1	selb	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	0	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2730000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	108066000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	234500000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	36500000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q1	selb	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P4Y
CY2021Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2020Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD

Files In Submission

Name	View Source	Status
0001453687-21-000069-index-headers.html	Edgar Link	pending
0001453687-21-000069-index.html	Edgar Link	pending
0001453687-21-000069.txt	Edgar Link	pending
0001453687-21-000069-xbrl.zip	Edgar Link	pending
exhibit101_dircompprogram.htm	Edgar Link	pending
exhibit311_03312021.htm	Edgar Link	pending
exhibit312_03312021.htm	Edgar Link	pending
exhibit321_03312021.htm	Edgar Link	pending
exhibit322_03312021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20210331.htm	Edgar Link	pending
selb-20210331.xsd	Edgar Link	pending
selb-20210331_cal.xml	Edgar Link	unprocessable
selb-20210331_def.xml	Edgar Link	unprocessable
selb-20210331_htm.xml	Edgar Link	completed
selb-20210331_lab.xml	Edgar Link	unprocessable
selb-20210331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2021 Q1 Form 10-Q Financial Statement

#000145368721000069 Filed on May 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2021 Q1 Form 10-Q Financial Statement

#000145368721000069 Filed on May 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac